Wall Street’s consensus price targets for Ardelyx imply a 92.12% upside from current levels. This projection is based on 12 recent analyst reports, with the highest target set at a 110% increase and the most conservative at 60%. Analysts cite the company’s late-stage pipeline, particularly its NHE3 inhibitor program for chronic kidney disease, as the primary driver of bullish sentiment. The average target revision over the past month has been an upward adjustment of 8.5%.

Over the past quarter, sell-side firms have revised their 2026 earnings per share (EPS) forecasts for Ardelyx upward by an average of 12%. Six of eight covering analysts raised estimates, with the median 2026 EPS projection now standing at $0.86 per share, compared to $0.77 three months ago. Consensus 2027 EPS forecasts have climbed 9%, reflecting growing confidence in commercial uptake of the company’s marketed therapies and potential milestone payments from collaboration partners.

Ardelyx shares surged 5.5% in the latest trading session on volume that was 35% above its 30-day average. Trading desks report that more than 4.8 million shares changed hands, compared to a typical daily volume of 3.6 million. Institutional block trades accounted for approximately 28% of today’s volume, suggesting renewed interest from hedge funds and mutual funds. The price breakout occurred after the company announced an updated manufacturing agreement designed to boost production capacity by 50% in 2027.